Researchers at Stanford University have identified what appears to be the root cause of lupus: a common virus that most people carry dormant in their cells.
Epstein-Barr virus (EBV) infects roughly 90% of adults at some point, usually in childhood, and typically causes no lasting harm. But for people who develop lupus—a chronic autoimmune disease affecting about 69,000 people in the UK—the virus appears to flip a dangerous switch.
The Discovery
The Stanford team found that EBV is vastly more prevalent in the immune cells of lupus patients. In healthy people, fewer than 1 in 10,000 B cells (a type of immune cell) host the dormant virus. In lupus patients, that jumps to roughly 1 in 400—a 25-fold difference.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxMore critically, the virus tends to hide in B cells that are already primed to attack the body's own tissues. When EBV activates these "autoreactive" cells, they don't just become hyperactive themselves. They recruit other immune cells, including killer T-cells, to join the attack on healthy tissue. The result: the joint pain, extreme fatigue, skin rashes, and systemic inflammation that define lupus.
"We think it applies to 100% of lupus cases," said William Robinson, the study's senior author and a professor of immunology and rheumatology at Stanford. "I think it really sets the stage for a new generation of therapies."
The research was published in Science Translational Medicine, and the finding matters because lupus has long been a puzzle. Doctors knew it was autoimmune—the body attacking itself—but didn't understand what triggered it. Knowing EBV is the culprit opens a direct path to treatment.
What Comes Next
Clinical trials for an EBV vaccine are already underway. Several research teams are also exploring whether cancer treatments designed to suppress B cells might help severe lupus cases. Neither approach is ready for patients yet, but both are grounded in something concrete: a mechanism that can actually be interrupted.
Other risk factors for lupus remain relevant—being female, for instance, because estrogen amplifies B-cell activity, and having African, Caribbean, or Asian ancestry. But identifying EBV as the trigger suggests these factors work through the virus, not independently of it.
This is the kind of discovery that doesn't immediately cure anyone, but it does something perhaps more valuable: it turns an unsolved mystery into a solvable problem.
